⌕
Cytokinetics · CYTK · Nasdaq
Tenet 34 · Weak
Compare
$51.65−2.86%At closeTenet 34 · Weak
$51.65−1.52 (−2.86%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Cytokinetics (CYTK) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

10 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue compounds ~5.7%/yr (FY21→FY25), net margin −891.6%. Worth your attention in FY25: Share count (+56.2%) and Capex step-up ($24.8M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲376.6%
88.0
FY21→FY25CAGR +5.7%/yr
Net income ($M)▼33.2%
−785.0
FY21→FY25CAGR —
Free cash flow ($M)▼33.8%
−534.8
capex stepped upCAGR —
Diluted EPS▼24.3%
−6.54
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+56.2%

76.9mn → 120.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$24.8M

▲535% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)88.0Revenue0.0COGS−416.0R&D−284.3SG&A−612.3Op income−172.7Tax & other−785.0Net income

-892¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -891.6% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
113.388.018.57.594.670.4▲376.6%+5.7%
Cost of revenue
3.70.00.00.00.00.0——
Gross profit
109.6—A—A—A—A70.4——
Research & development
402.9416.0339.4330.1240.8159.9▲22.6%+27.0%
Selling, general & admin
414.2284.3215.3173.6178.096.8▲32.0%+30.9%
Total operating expenses
817.8700.3554.7503.7418.8256.7▲26.2%+28.5%
Operating incomefeeds ROC rank
−708.2−612.3−536.2−496.2−324.2−186.3▼14.2%—
Other income, net
−122.0−221.1−104.8−57.7−76.1−29.3——
Pretax income
−830.2−833.4−641.1−553.9−400.3−215.6▼30.0%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−777.9−785.0−589.5−526.2−389.0−215.3▼33.2%—
Per share
Diluted EPSbuyback-sensitive
−6.05−6.54−5.26−5.45−4.33−2.80▼24.3%—
Diluted shares (mn)
139.04120.10111.9896.5289.8376.89▲7.3%+11.8%
Margins
Gross margin94th pct in Healthcare
96.7%—A—A—A—A100.0%——
Operating margin
−625.2%−695.4%−2902.7%−6589.7%−342.8%−264.5%▲2207.3pp−430.9pp
Net margin4th pct in Healthcare
−686.6%−891.6%−3191.1%−6988.6%−411.2%−305.7%▲2299.5pp−585.9pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Cytokinetics' revenue last fiscal year?

Cytokinetics reported revenue of $88.0M in fiscal 2025, up 376.6% from fiscal 2024.

What was Cytokinetics' net income?

Cytokinetics reported net income of −$785.0M in fiscal 2025, a net margin of −891.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.